A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
Recruiting now · Phase 1
Conditions studied: Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
In brief
This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.
Key facts
- Study ID
- NCT07189403
- Run by
- Daiichi Sankyo
- People needed
- 40
- Starts
- 2025-11-04
- Expected to finish
- 2028-03-01
- Last updated by the study team
- 2026-05-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Florida Cancer Specialists — Sarasota, Florida, United States (enrolling)
- Columbia University — New York, New York, United States (enrolling)
- Brown University — Providence, Rhode Island, United States (enrolling)
- Oncopole Claudius Regaud — Toulouse, France (enrolling)
- Centre Oscar Lambret — Villejuif, France
- Royal Marsden — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.